Clinical trial
A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America
NCT00360529 is registered in ClinicalTrials.gov with Sprout Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America
- Lead sponsor
- Sprout Pharmaceuticals, Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- April 30, 2008
- Enrollment
- 880 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.